Dr. Paul Sax wraps up a two-part series on long-acting cabotegravir-rilpivirine, in
HIV and ID Observations.
In the latest HIV and ID Observations, Dr. Paul Sax discusses the limitations of the HIV therapeutic long-acting cabotegravir-rilpivirine and demonstrates why this treatment is anything but simple. Read part one here.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.
Want to see more from NEJM Journal Watch? Register here.